Comment
doi: 10.1016/S1470-2045(09)70391-2.
Epub 2009 Dec 23.
IGF-1R targeted treatment of sarcoma
- PMID: 20036195
- DOI: 10.1016/S1470-2045(09)70391-2
Item in Clipboard
Comment
IGF-1R targeted treatment of sarcoma
Lancet Oncol.
2010 Feb.
No abstract available
Comment on
-
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.Lancet Oncol. 2010 Feb;11(2):129-35. doi: 10.1016/S1470-2045(09)70354-7. Epub 2009 Dec 23. Lancet Oncol. 2010. PMID: 20036194 Free PMC article. Clinical Trial.
Similar articles
-
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.Eur J Cancer. 2012 Nov;48(16):3027-35. doi: 10.1016/j.ejca.2012.05.009. Epub 2012 Jun 7. Eur J Cancer. 2012. PMID: 22682017
-
Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?J Clin Oncol. 2011 Dec 1;29(34):4581-3. doi: 10.1200/JCO.2011.38.2374. Epub 2011 Oct 24. J Clin Oncol. 2011. PMID: 22025158 Free PMC article. No abstract available.
-
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.Lancet Oncol. 2010 Feb;11(2):129-35. doi: 10.1016/S1470-2045(09)70354-7. Epub 2009 Dec 23. Lancet Oncol. 2010. PMID: 20036194 Free PMC article. Clinical Trial.
-
IGF-1R as an anti-cancer target--trials and tribulations.Chin J Cancer. 2013 May;32(5):242-52. doi: 10.5732/cjc.012.10263. Epub 2013 Apr 19. Chin J Cancer. 2013. PMID: 23601239 Free PMC article. Review.
-
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.Cancer J. 2010 May-Jun;16(3):183-94. doi: 10.1097/PPO.0b013e3181dbebf9. Cancer J. 2010. PMID: 20526094 Review.
Cited by
-
Antitumor effects of β-elemene via targeting the phosphorylation of insulin receptor.Endocr Relat Cancer. 2019 Feb;26(2):187-199. doi: 10.1530/ERC-18-0370. Endocr Relat Cancer. 2019. PMID: 30422809 Free PMC article.
-
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.J Clin Oncol. 2024 Nov;42(31):3725-3734. doi: 10.1200/JCO.24.00020. Epub 2024 Jul 2. J Clin Oncol. 2024. PMID: 38954782 Clinical Trial.
-
Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.Annu Rev Pathol. 2012;7:145-59. doi: 10.1146/annurev-pathol-011110-130237. Epub 2011 Sep 19. Annu Rev Pathol. 2012. PMID: 21942527 Free PMC article. Review.
-
Treatment of Bone Tumors.Surg Pathol Clin. 2012 Mar;5(1):301-18. doi: 10.1016/j.path.2011.07.015. Surg Pathol Clin. 2012. PMID: 22328909 Free PMC article.
-
PRAS40 deregulates apoptosis in Ewing sarcoma family tumors by enhancing the insulin receptor/Akt and mTOR signaling pathways.Am J Cancer Res. 2016 Jan 15;6(2):486-97. eCollection 2016. Am J Cancer Res. 2016. PMID: 27186418 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
